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Abstract: Signs and symptoms of depression can be linked to one or more monoaminergic 
systems, specifically the norepinephrine (NE), the dopamine (DA), and the serotonin (5-HT) 
systems. In particular, the modulation of energy, vigilance, and arousal can be directly linked 
to the NE system. There is, however, a great deal of overlap in the modulation of the symptoms 
of depression between these monoaminergic systems. There are considerable reciprocal interac-
tions between the NE, DA, and the 5-HT systems. When using a selective serotonin reuptake 
inhibitor (SSRI), for example, 5-HT transmission is enhanced, but at the same time there is 
a dampening of the activity of NE and DA neurons through inhibitory 5-HT2A and 5-HT2C 
receptors, respectively. This could explain the residual symptoms of fatigue, lack of energy, 
and anhedonia, often seen after patients present an overall positive response to a SSRI. Using a 
dual 5-HT and NE reuptake inhibitor (SNRI), such as milnacipran, would result in an additional 
increase in NE activity. Futhermore, inhibiting NE reuptake increases DA availability in the 
frontal cortex since DA is mainly cleared by the NE transporters in several brain regions. A risk 
inherent in increased NE activity is that of provoking anxiety. This is avoided however by the 
attenuation of the phasic reactivity of the firing of NE neurons through prolonged   administration 
of SSRI and SNRI.
Keywords: norepinephrine, dopamine, serotonin, residual symptoms, norepinephrine 
paradox
Introduction
Noradrenergic pathways in the brain originate mainly in the locus coeruleus and project 
to the cortex, limbic regions, and hindbrain. They are involved in the regulation of 
energy levels, vigilance, reactivity, and executive function. Noradrenergic stimula-
tion dampens noise in both excitatory and inhibitory circuits thus enhancing signal to 
noise in the target areas.1
The functions of norepinephrine (NE) and dopamine (DA) are closely linked. The DA 
system is extremely complex due to the multitude of DA receptor subtypes, their locations, 
and functions. The nigrostriatal DA pathway, which projects from the substantia nigra to 
the basal ganglia, is part of the extrapyramidal system and plays a key role in regulating 
movement. DA deficiency can thus result in Parkinsonism with tremor, rigidity, and 
akinesia/bradykinesia. The mesolimbic DA pathway originates from dopaminergic cell 
bodies in the ventral tegmental area of the brainstem and projects to limbic regions of the 
brain. These pathways play an important role in emotional behavior, such as pleasurable 
sensations, the euphoria experienced with drugs of abuse, and the delusions and halluci-
nations of psychosis. Mesocortical DA projections mediate cognitive   functions, such as Neuropsychiatric Disease and Treatment 2011:7 (Suppl 1) submit your manuscript | www.dovepress.com
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verbal   fluency, focus, serial   learning, executive functioning, 
focusing and sustaining attention, prioritizing behavior, and 
modulating social behavior.1
The effects of NE, serotonin (5-HT), and DA overlap in the 
brain and all three transmitters are implicated in the   symptoms of 
depression. The three neurotransmitters are involved in mood, 
emotion, cognition, and chronic pain. Symptoms associated 
with vigilance, arousal,   interest, and energy are most closely 
associated with NE neurotransmission while   impulsivity is 
associated with 5-HT   neurotransmission, and symptoms asso-
ciated with drive are related to DA   neurotransmission. Thus, 
depressive symptoms may result from dysfunction of any or 
all of the monoamine   neurotransmitter systems.1
Residual symptoms
Remission, usually defined as a score of 7 or less on the 
Hamilton depression rating scale (HAMD) or 10 or less on 
the Montgomery–Asberg depression rating scale (MADRS), 
does not necessarily mean a total absence of all symptoms. 
Residual symptoms are present in 30% to 50% of patients 
in remission. In addition to the reduced quality of life this 
causes, relapse rates are 3 to 6 times higher in patients with 
residual symptoms.2,3
The nature of the residual symptoms can vary depending 
on the nature of the initial depression and antidepressant 
used4 but in general, fatigue (both mental and physical), 
concentration difficulties, decreased interest or pleasure, 
cognitive impairment, and anxiety are among the most 
common residual symptoms.3,5 For example, in a study of 
215 patients with major depressive disorder who received 
fluoxetine for 8 weeks, 108 were found to be in remission 
(HAMD # 7).6 Of these, however, only 18% had no threshold 
or subthreshold symptoms of major depression, while 26% 
had one residual symptom, and over half (57%) still had 2 
or more symptoms. The question can be asked as to whether 
these remaining symptoms are true residual symptoms or 
iatrogenic symptoms caused by the antidepressants used 
to treat the disorder.2,3 In order to answer this question it is 
necessary to examine the interaction between 5-HT and NE 
and DA neurotransmission.
Interaction between 5-HT and NE 
neurotransmission
5-HT projections from the raphe nucleus to the locus 
  coeruleus impose a tonic inhibitory tone on the firing of 
NE neurons. When this inhibition is removed, NE firing and 
release are increased. This has been shown in animal   studies 
where brain 5-HT levels were reduced by administration 
of the 5-HT synthesis inhibitor, p-chlorophenylalanine7 
  or by lesion of the raphe nucleus using the specific 5-HT 
neuron toxin, 5,7-dihydroxytryptamine (5,7-DHT).8 In both 
cases removal of the serotonergic influence on the locus 
coeruleus led to a significant increase in firing of the NE 
neurons.
If the serotonergic inhibition of NE neurotransmission 
is increased, as during treatment with a selective sero-
tonin reuptake inhibitor (SSRI), NE firing and release are 
decreased. Sustained administration of the SSRI, citalopram, 
for 21 days, (20 mg/kg/d sc using osmotic minipumps) pro-
duced a progressive decrease in spontaneous firing activity 
of NE neurons in the locus coeruleus.9 Similarly, subacute 
and long-term treatment with the SSRI, escitalopram, 
decreased NE neuronal firing. Blockade of this effect by 
selective antagonists showed that the effect was mediated 
by the 5-HT2A receptor.7
The effects of chronic administration of citalopram are 
also seen on the levels of extracellular NE in the brain. 
Brain microdialysis was used to determine the extracellular 
NE in conscious rats. In rats treated daily for 14 days with 
citalopram (10 mg/kg/day sc), NE levels in the dialysate 
showed a significant decrease in the basolateral nucleus of 
the amygdala.10
Interaction between 5-HT and DA 
neurotransmission
In addition to its tonic inhibition of NE transmission, 5-HT 
also inhibits the firing of DA neurons. Selective lesion of 
5-HT neurons by 5,7-DHT enhanced the firing activity of 
DA neurons in the ventral tegmental area by 36%, indicating 
the presence, under normal conditions, of a tonic inhibitory 
effect of 5-HT on these DA neurons.11 Sustained administra-
tion of escitalopram robustly decreased the firing rate of DA 
neurons. This inhibition was reversed by a selective 5-HT2C 
receptor antagonist.7
Thus 5-HT exerts a tonic inhibition on NE neurons 
through 5-HT2A receptors and a tonic inhibition of DA 
  neurons through 5-HT2C receptors.
Residual or iatrogenic symptoms?
SSRI treatment results in a sustained increase of 5-HT 
  activity and thus an increased inhibitory tone which leads 
to a decrease of both NE and DA neurotransmission. These 
two neurotransmitters are closely implicated in the regulation 
of the many frequent residual symptoms, namely, fatigue, 
decreased concentration, decreased interest or pleasure, 
  cognitive impairment, and anxiety. Thus it is possible that Neuropsychiatric Disease and Treatment 2011:7 (Suppl 1) submit your manuscript | www.dovepress.com
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these “residual” symptoms could be, at least in part, the result 
of SSRI treatment and thus “iatrogenic”.
The effects of milnacipran
The serotonin norepinephrine reuptake inhibitor (SNRI), 
milnacipran, is unique in as much as it blocks the reuptake 
of both 5-HT and NE with similar affinity without any effects 
on postsynaptic receptors.12,13 As with SSRIs, milnacipran 
inhibits the firing of NE neurons in the locus coeruleus.14 
Unlike SSRIs, however, milnacipran also blocks the reuptake 
of NE. Microdialysis studies have shown that, unlike SSRIs, 
which after chronic administration increase 5-HT levels7,9,10 
but decrease NE levels, both acute and subacute adminis-
tration of milnacipran increase extracellular levels of both 
5-HT and NE.15,16
Although it has no affinity with the DA transporter 
(and does not block the reuptake of DA),12,13 milnacipran 
increases DA levels, as well as NE and 5-HT levels, in the 
frontal cortex.16,17 Although the exact nature of this effect 
has not yet been determined a probable mechanism can be 
proposed. The NE transporter has similar affinities for NE 
and DA.18 Since DA is relatively abundant compared with 
DA transporters in the prefrontal cortex19 it can be taken 
up non-selectively by NE transporters in this region20 and 
co-released with NE.21 The selective NE uptake inhibitors, 
reboxetine and atomoxetine, which have no affinity with the 
DA transporter, have been shown to increase extracellular 
DA levels as well as NE levels in the prefrontal cortex, but 
not in the nucleus accumbens.22,23 The inhibition of the NE 
transporter by milnacipran therefore results in an increase in 
the extracellular levels of both NE and DA.
In contrast to the SSRIs, milnacipran increases extra-
cellular levels of NE and DA which may compensate for 
the decreased firing of NE neurons. Clinically this could 
translate into less reduced residual (iatrogenic?) symptoms 
compared with treatment with SSRIs. No studies have yet 
analyzed the comparative frequencies of residual symptoms 
with   milnacipran and SSRIs. However a recent study com-
paring the SSRI, escitalopram with the SNRI, duloxetine, 
found that patients on the SNRI had greater improvement 
in cognitive function in the remission phase, and in the 
recovery phase.24
The noradrenergic paradox
There is strong evidence of a close relationship between 
NE stimulation and the induction of anxiety states.25 If 
  milnacipran increases synaptic levels of NE (and DA) why 
does it not increase anxiety?
The effects of NE neurotransmission on the function of 
the prefrontal cortex can be described by an inverted U shape 
(Figure 1).26 Very low levels of NE (and DA) transmission 
result in cognitive impairment, inattention, and drowsiness. 
Optimal levels of NE neurotransmission lead to enhanced 
cognitive performance and executive functions that guide 
behavior, thought, and affect (Table 1). Very high levels of 
NE stimulation produce cognitive impairment, anxiety, and 
even dysphoric psychosis. Thus one might expect chronic 
NE reuptake inhibition with milnacipran to increase anxiety 
symptoms. This, however, does not happen.27 Indeed several 
studies have shown that milnacipran decreases anxiety both 
in animal models of anxiety,28 in anxio-depressive29 and 
anxio-schizophrenic patients.30
A possible reason is that there are two types of NE firing 
pattern in the brain: tonic and phasic.31 Tonic firing is the 
steady-state, background firing that occurs at rest. It correlates 
with behavioral arousal at rest (awake, alert). Mechanistically 
it involves exocytotic release of NE at the nerve terminal. 
Phasic reactivity, on the other hand, occurs in response to a 
stimulus. It correlates with threat or stress-induced anxiety-
like behavior or, in extreme cases, a panic attack. It can last 
from seconds to minutes or longer. It increases vigilance 
(hypervigilance), enhances sensorimotor reflex responses, 
increases acoustic startle reflex, and reduces immobility and 
facilitates active escape behaviors (fight or flight response 
to an aversive stimulus). It is a result of robust increases in 
NE neuron firing. A certain amount of phasic reactivity is 
necessary for survival, but too much (as in anxiety disorders 
and anxious depression and panic disorder) is maladaptive.
In the depressed state, with no threatening stimulus, 
tonic NE activity (exocytotic release) at rest is low. The low 
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Figure  1  Norepinephrine  (NE)  and  dopamine  (DA)  neurotransmission  in  the 
prefrontal cortex and executive function. NE and DA in arrows represent increasing 
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Dovepress 
Dovepress
18
Blier and Briley
basal firing rate of NE neurons combined with an efficient 
reuptake may lead to very low extracellular NE levels in 
the prefrontal cortex resulting in fatigue, somnolence, and 
cognitive impairment.31–33 This corresponds to the left-hand 
end of the inverted-U curve (Figure 1).
In the face of acute stress or a threatening stimulus, NE 
neurons (with low tonic, baseline levels of NE exerting only 
a minimal inhibition, via the somatodendritic α2-receptors, 
on the firing of neurons in the locus coeruleus) would 
respond with very high phasic reactivity (a sharp increase 
in neuronal firing). This important increase in firing would 
greatly increase extracellular NE to levels corresponding to 
the far right-hand end of the inverted-U curve (Figure 1). 
Clinically this would produce cognitive impairment, anxiety/
panic, and dysphoric psychosis.14,31–33
Although it increases NE (and DA) neurotransmission 
in the prefrontal cortex, milnacipran does not cause anxiety. 
This NE paradox is explained by the different adaptation to 
chronic drug treatment of the two types of firing.31
The effect of acute and long-term 
milnacipran treatment on 5-HT  
and NE neurotransmission
Acute treatment with milnacipran (Figure 2a) results in 
increased synaptic concentrations of 5-HT but decreased 
firing of the 5-HT neurons in the raphe nucleus possibly as a 
result of increased stimulation of the inhibitory somatoden-
dritic autoreceptors. Long-term treatment results in a further 
increase in synaptic concentrations of 5-HT due to desensi-
tization of terminal autoreceptors controlling the release of 
5-HT. Neuronal firing has been shown to recover to normal 
levels in the presence of SSRI or milnacipran.14 The ensuing 
enhanced 5-HT neurotransmission may thus contribute to 
its antidepressant effect. The increased 5-HT transmission 
by SSRI would also act to inhibit NE   neurotransmission. 
Decreased NE phasic reactivity (NE firing) would lead to 
an anxiolytic effect, but the decreased tonic NE   activity 
Table 1 Executive function in the prefrontal cortex and its effect 
on behavior, thought and affect
Executive function in the prefrontal cortex
•   Regulates working memory (maintains task relevant information when 
stimuli are no longer present in the environment)
• Inhibits inappropriate responses (impulse control)
• Suppresses distractions (attention)
• Promotes organization and planning
• Stimulates purposeful behavior (implementation)
• Integrates cognition with emotion
Summarized from references 26,37.
Figure 2 Scheme of the activity of 5-HT (A) and norepinephrine (NE) (B) neurotransmission during treatment with milnacipran. A) 5-HT system. Acute treatment with 
milnacipran results in a decreased firing of 5-HT neurons from the raphe nucleus possibly due in part to increased stimulation of somatodendritic autoreceptors. Long-
term treatment with milnacipran results in a full recovery in the firing rate of 5-HT neurons in the presence of milnacipran thereby leading to a net increase in 5-HT 
neurotransmission. Contributing to this enhancement are: 1) the normalized firing rate of 5-HT neurons in the presence of milnacipran 2) the desensitization of the terminal 
5-HT1B autoreceptor, and 3) the desensitization of the α2-adrenergic heteroreceptors on 5-HT terminals. B) NE system. Acute treatment with milnacipran results in 
increased synaptic concentrations of NE but decreased firing of the NE neurons of the locus coeruleus due to increased stimulation of the somatodendritic α2-adrenergic 
autoreceptors. Long-term treatment with milnacipran results in a further increase in synaptic concentrations of NE due to desensitization of presynaptic autoreceptors. The 
somatodendritic α2-adrenergic autoreceptors do not desensitize.
Acute treatment with milnacipran
Long-term treatment with milnacipran
Normal
A B
Acute treatment with milnacipran
Normal
Long-term treatment with milnacipranNeuropsychiatric Disease and Treatment 2011:7 (Suppl 1) submit your manuscript | www.dovepress.com
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(NE release) could potentially lead to side effects (or residual 
symptoms) such as, fatigue, apathy, low interest,   indifference, 
and cognitive dulling.
Treatment with milnacipran, however, will also act 
upon NE neurotransmission. Acute treatment will   (Figure 2b) 
result in increased synaptic concentrations of NE but 
decreased firing of the NE neurons in the locus coeruleus 
through stimulation of inhibitory somatodendritic autore-
ceptors. Long-term treatment results in a further increase 
in synaptic concentrations of NE due to desensitization of 
terminal autoreceptors (controlling the release of NE). The 
enhanced NE neurotransmission may thus contribute to the 
antidepressant effect. In contrast to terminal α2-adrenergic 
autoreceptors controlling NE release, long-term blockade 
of the NE transporter does not desensitize somatodendritic 
α2-adrenergic autoreceptors which control NE firing34,35 so 
that the firing of the NE neurons remains suppressed. This 
phenomenon has been recently reviewed.36 This decreased 
phasic NE reactivity may contribute to the anxiolytic effect. 
The enhanced tonic NE activity however, should poten-
tially reduce the risk of the long-term side effects (residual 
symptoms?) seen with SSRIs. In addition the low phasic 
NE reactivity may protect against the acute stress-induced 
anxiety or panic attacks following long-term NE reuptake 
inhibition in part also due to the desensitization of excitatory 
β-adrenergic receptors on postsynaptic neurons.
Conclusion
The signs and symptoms of depression are modulated by 
changes in NE, 5-HT, and DA neurotransmission. Reduced 
NE activity may contribute to symptoms such as fatigue, 
apathy, low interest, indifference, and decreased cognitive 
performance.
SSRIs may contribute to residual symptoms by   dampening 
NE and DA neuronal activity. Milnacipran, which increases 
NE (and DA) as well as 5-HT neurotransmission, is expected 
to improve depressive symptoms without causing iatrogenic 
residual symptoms. Milnacipran increases tonic NE activity, 
while attenuating phasic NE reactivity. Its action on the three 
monoamine neurotransmitters contributes to its antidepres-
sant action while its attenuation of phasic NE reactivity may 
decrease the risk of anxiety.
Disclosures
Dr Pierre Blier has received research support from, spoken 
for, or sits on advisory boards for the following companies: 
AstraZeneca, Biovail, Bristol-Myers Squibb, Eli Lilly, 
Cyberonics, Janssen-Ortho, Jazz Pharmaceuticals, Pierre 
Fabre Medicaments, Labopharm, Lundbeck/Takeda, Merck, 
Schering-Plough, Sanofi-Synthélabo, Servier, Shire and 
Wyeth. Dr Mike Briley is a consultant for Pierre Fabre 
Médicament, Asahi Kasei Pharma, Germania Pharmaceutica, 
Janssen Pharmaceutica, and Cypress BioScience.
References
  1.  Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific 
Basis and Practical Applications. 3rd ed. Cambridge, UK: Cambridge 
University Press; 2008.
  2.  Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, 
reduced positive affect: the role of catecholamines in causation and 
cure. J Psychopharmacol. 2007;21:461–471.
  3.  Trivedi MH, Hollander E, Nutt D, Blier P. Clinical evidence and potential 
neurobiological underpinnings of unresolved symptoms of depression. 
J Clin Psychiatry. 2008;69:246–258.
  4.  Kurian BT, Greer TL, Trivedi MH. Strategies to enhance the therapeutic 
efficacy of antidepressants: targeting residual symptoms. Expert Rev 
Neurother. 2009;9:975–984.
  5.  Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) 
symptoms during depressive episodes and periods of remission: a 3-year 
prospective study. Psychol Med. 2011. In press.
  6.  Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in 
depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 
1999;60:221–225.
  7.  Dremencov E, El Mansari M, Blier P. Noradrenergic augmentation of 
escitalopram response by risperidone: electrophysiologic studies in the 
rat brain. Biol Psychiatry. 2007;61:671–678.
  8.  Haddjeri N, de Montigny C, Blier P. Modulation of the firing 
  activity of noradrenergic neurones in the rat locus coeruleus by the 
5-hydroxtryptamine system. Br J Pharmacol. 1997;120:865–875.
  9.  Szabo ST, de Montigny C, Blier P. Progressive attenuation of the fir-
ing activity of locus coeruleus noradrenergic neurons by   sustained 
administration of selective serotonin reuptake inhibitors. Int J   
Neuropsychopharmacol. 2000;3:1–11.
  10.  Kawahara Y, Kawahara H, Kaneko F, Tanaka M. Long-term 
  administration of citalopram reduces basal and stress-induced extra-
cellular noradrenaline levels in rat brain. Psychopharmacology (Berl). 
2007;194:73–81.
  11.  Guiard BP, El Mansari M, Merali Z, Blier P. Functional interactions 
between dopamine, serotonin and norepinephrine neurons: an in-vivo 
electrophysiological study in rats with monoaminergic lesions. Int 
J Neuropsychopharmacol. 2008;11:625–639.
  12.  Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M. 
  Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-
aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a 
potential fourth generation antidepressant drug. Neuropharmacology. 
1985;24:1211–1219.
  13.  Koch S, Hemrick-Luecke SK, Thompson LK, et al. Comparison of 
effects of dual transporter inhibitors on monoamine transporters and 
extracellular levels in rats. Neuropharmacology. 2003;45:935–944.
  14.  Mongeau R, Weiss M, de Montigny C, Blier P. Effect of acute, 
short- and long-term milnacipran administration on rat locus 
coeruleus   noradrenergic and dorsal raphe serotonergic neurons. 
Neuropharmacology. 1998;37:905–918.
  15.  Moret C, Briley M. Effects of milnacipran and pindolol on   extracellular 
noradrenaline and serotonin levels in guinea pig hypothalamus. 
J   Neurochem. 1997;69:815–822.
  16.  Kitaichi Y, Inoue T, Izumi T, Nakagawa S, Kato A, Koyama T. 
Subchronic milnacipran treatment increases basal extracellular 
  noradrenaline concentrations in the medial prefrontal cortex of rats. 
Eur J Pharmacol. 2005;520:37–42.
  17.  Kitaichi Y, Inoue T, Nakagawa S, Izumi T, Koyama T. Effect of mil-
nacipran on extracellular monoamine concentrations in the medial 
prefrontal cortex of rats pre-treated with lithium. Eur J Pharmacol. 
2005;516:219–226.Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing on 
concise rapid reporting of clinical or pre-clinical studies on a range of 
neuropsychiatric and neurological disorders. This journal is indexed on 
PubMed Central, the ‘PsycINFO’ database and CAS, and is the official 
journal of The International Neuropsychiatric Association (INA). The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Neuropsychiatric Disease and Treatment 2011:7 (Suppl 1) submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
20
Blier and Briley
  18.  Raiteri M, Del Carmine R, Bertollini A, Levi G. Effect of 
  sympathomimetic amines on the synaptosomal transport of 
  noradrenaline, dopamine and 5-hydroxytryptamine. Eur J Pharmacol. 
1977;41:133–143.
  19.  Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI.   Dopamine 
axon varicosities in the prelimbic division of the rat prefrontal 
  cortex exhibit sparse immunoreactivity for the dopamine transporter. 
J   Neurosci. 1998;18:2697–2708.
  20.  Yamamoto BK, Novotney S. Regulation of extracellular dopamine by 
the norepinephrine transporter. J Neurochem. 1998;71:274–280.
  21.  Devoto P, Flore G, Pani L, Gessa GL. Evidence for co-release of nora-
drenaline and dopamine from noradrenergic neurons in the cerebral 
cortex. Mol Psychiatry. 2001;6:657–664.
  22.  Linnér L, Endersz H, Ohman D, Bengtsson F, Schalling M,   Svensson TH. 
Reboxetine modulates the firing pattern of dopamine cells in the ventral 
tegmental area and selectively increases dopamine availability in the 
prefrontal cortex. J Pharmacol Exp Ther. 2001;297:540–546.
  23.  Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extra-
cellular levels of norepinephrine and dopamine in prefrontal cortex of 
rat: a potential mechanism for efficacy in attention deficit/hyperactivity 
disorder. Neuropsychopharmacology. 2002;27:699–711.
  24.  Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Abarca JE, et al. Major 
Depressive Disorder in recovery and neuropsychological functioning: 
effects of selective serotonin reuptake inhibitor and dual inhibitor 
depression treatments on residual cognitive deficits in patients with 
Major Depressive Disorder in recovery. J Affect Disord. 2010;123: 
341–350.
  25.  Itoi K, Sugimoto N. The brainstem noradrenergic systems in stress, 
anxiety and depression. J Neuroendocrinol. 2010;22:355–361.
  26.  Hains AB, Arnsten AF. Molecular mechanisms of stress-induced 
prefrontal cortical impairment: implications for mental illness. Learn 
Mem. 2008;15:551–564.
  27.  Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, 
clinical efficacy, and tolerability in comparison with other classes of 
antidepressants. CNS Spectr. 2005;10:732–747.
  28.  Moojen VK, Martins MR, Reinke A, et al. Effects of milnacipran in 
animal models of anxiety and memory. Neurochem Res. 2006;31: 
571–577.
  29.  Selitskiĭ GV , Kaprin AD, Izvozchikov SB, Bolotov AV , Troshina AV .   
Milnacipran (ixel) in the treatment of anxiodepressive and sexual disor-
ders in patients with noninflammatory syndrome of chronic pelvic pain. 
Ter Arkh. 2007;79:81–84.
  30.  Gama CS, Zanatto VC, Picon F, Lobato MI, Belmonte-de-Abreu PS. 
Efficacy of milnacipran in treating anxiety symptoms in schizophrenic 
patients receiving clozapine: a case series study. Rev Bras Psiquiatr. 
2006;28:339–340.
  31.  Morilak DA, Frazer A. Antidepressants and brain monoaminergic 
systems: a dimensional approach to understanding their behavioural 
effects in depression and anxiety disorders. International Journal of 
Neuropsychopharmacology. 2004;7:193–218.
  32.  Szabo ST, Blier P. Functional and pharmacological characterization of 
the modulatory role of serotonin on the firing activity of locus coeruleus 
norepinephrine neurons. Brain Res. 2001;922:9–20.
  33.  Parini S, Renoldi G, Battaglia A, Invernizzi RW. Chronic reboxetine 
desensitizes terminal but not somatodendritic alpha2-adrenoceptors 
controlling noradrenaline release in the rat dorsal hippocampus. 
  Neuropsychopharmacology. 2005;30:1048–1055.
  34.  Crews FT, Smith CB. Presynaptic alpha-receptor subsensitivity after 
long-term antidepressant treatment. Science. 1978;202:322–324.
  35.  McMillen BA, Warnack W, German DC, Shore PA. Effects of chronic 
desipramine treatment on rat brain noradrenergic responses to alpha-
adrenergic drugs. Eur J Pharmacol. 1980;61:239–246.
  36.  El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P. 
Relevance of norepinephrine-dopamine interactions in the treatment of 
major depressive disorder. CNS Neurosci Ther. 2010;16:e1–e17.
  37.  Arnsten AF, Li BM. Neurobiology of executive functions:   catecholamine 
influences on prefrontal cortical functions. Biol   Psychiatry. 2005;57: 
1377–1384.